Virax Biolabs
VRAX | NASDAQ
$0.45
-$0.16 (-26.54%)
At close: Nov 16, 2026, 4:00 PM ET
$0.43
-$0.02 (-4.16%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-26.54%
(1D)No price chart data available for 1D timeframe.
Rating
31
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #779/1021 (Top 76%)
Key Statistics
Market Data
Market Cap $602.56K
1D Range
0.43 0.51
52W Range
0.43 17.20
Valuation (TTM)
PE -0.02
PB 0.08
EV/EBITDA N/A
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $1.00
Cash Flow
FCF Yield -1318.2%
SBC Adj. FCF Yield -1339.8%
SBC Impact -1.6%
Margins
Gross Margin -1480.5%
Operating Margin -64038.2%
FCF Margin -56607.7%
Growth (CAGR)
Revenue 3Y | 5Y -48.0% |
-36.9%
Dil EPS 3Y | 5Y 13.2% |
20.8%
FCF 3Y | 5Y -66.2% |
-19.8%
Returns
ROA -88.4%
ROE -114.2%
ROIC -100.0%
Financial Health
Net Cash
$6.49M
Current Ratio 9.97
Interest Coverage -96.86
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intende...
Sector Healthcare
Industry Biotechnology
Employees 26
IPO Date Jul 21, 2022
Website viraxbiolabs.com
Fiscal Year April - March
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$1.00
Upside
+122.22%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove VRAX